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Abstract 
Introduction: Heparins are common blood anticoagulants that are critical for many 
surgical and biomedical procedures used in modern medicine. In contrast to nat-
ural heparin derived from porcine gut mucosa, synthetic heparins are homoge-
nous by mass, polymer length, and chemistry. 
Materials & methods: Stable cell lines expressing the human and mouse Stabilin re-
ceptors were used to evaluate endocytosis of natural and synthetic heparin. We 
chemoenzymatically produced synthetic heparin consisting of 12 sugars (do-
decamers) containing 14 sulfate groups resulting in a non-3-O sulfated struc-
ture (n12mer). Half of the n12mer was modified with a 3-O sulfate on a single 
GlcNS sugar producing the 3-O sulfated heparin (12mer). Wildtype (WT), Stabi-
lin-1 knock-out (KO), and Stabilin-2 KO C57BL/6 mice were developed and used 
for metabolic studies and provided as a source for primary liver sinusoidal en-
dothelial cells. 
Results & conclusions: Human and mouse Stabilin-2 receptors had very similar en-
docytosis rates of both the 12mer and n12mer, suggesting that they are function-
ally similar in primary cells. Subcutaneous injections of the n12mer and 12mer 
revealed that the 12mer had a much longer half-life in circulation and a higher 
accumulation in liver. The n12mer never accumulated in circulation and was read-
ily excreted by the kidneys before liver accumulation could occur. Liver sinusoidal 
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endothelial cells from the Stabilin-2 KO mice had lower uptake rates for both do-
decamers, whereas, the Stabilin-1 KO mice had lower endocytosis rates for the 
12mer than the n12mer. 3-O sulfation of heparin is correlated to both a longer 
circulatory half-life and hepatotropism which is largely performed by the Stabi-
lin receptors. 
Keywords: Heparin, Liver sinusoidal endothelial cells, Stabilin, Liver, Kidney, 
Catabolism  
1. Introduction 
Heparin is a time-honored anticoagulant [1] for use in multiple therapeutic 
treatments including deep-vein thrombosis [2], kidney dialysis [3], venous 
thromboembolisms [4], and is used as a key tool to prevent blood coagu-
lation during and after surgery [5]. Heparin is a complex sugar-based poly-
mer composed of N-acetylglucosamine and glucuronic acid/iduronic acid 
with multiple sulfation sites [6]. The pattern and density of sulfation deter-
mines its affinity for the coagulation factors and other proteins and recep-
tors present in the cardiovascular and reticuloendothelial systems [7]. Hence, 
unfractionated heparin (UFH) has the highest affinity for many of the co-
agulation factors due to the greater average mass of the polymers (mean 
mass=13.5 kDa) and its high polydispersity. Low molecular weight heparin 
(LMWH) consists of the shorter length polymers (mean size=2.5 kDa) as it 
is prepared from the cleavage products of UFH [8]. LMWH is the most com-
mon form of heparin in clinical settings as it may be self-administered post-
surgically by the patient and available by prescription [9]. 
The most important modification of heparin for anticoagulation activity 
is the 3-O sulfation on N-acetylglucosamine. This sulfation is critical for the 
binding of anti-thrombin III [10] and prevents the processing of pro-fibrin 
into fibrin. The synthesis of heparin, which has been under development for 
the past eight years and is now nearly economically feasible, demonstrates 
that the sulfation of the 3-O position of GlcNS has the most impact on hep-
arin’s anticoagulation activity [11–14]. 3-O sulfation is also recognized by 
the clearance receptors for heparin and may impact anticoagulation tim-
ing and activity [15]. 
Clearance of systemic heparin is through the reticuloendothelial system 
[16] which involves both liver and kidney function. The clearance of UFH in-
volves liver, in contrast to LMWH which is primarily cleared via the kidneys 
[17,18]. Patients with renal impairment are    subject to increased care and 
scrutiny with LMWH administration due to kidney accumulation and bleed-
ing complications that may arise [19–21]. The molecular mechanism of hep-
arin clearance is largely mediated by the Stabilin-2 receptor [22] which is 
expressed in liver, spleen, lymph nodes, bone marrow, and in specialized 
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structures of the kidney, heart, brain, and eye [23]. Stabilin-2 is a type I recep-
tor and is expressed as two isoforms, a full 315-HARE isoform, and a proteo-
lytically cleaved 190-HARE isoform that retains full functionality as the larger 
isoform. Stabilin-2 is a constitutively active receptor that uses the clathrin-
coat mechanism for rapid internalization with or without ligand [24,25]. Sim-
ilarly, a close homologue of Stabilin-2, Stabilin-1, is expressed by a wide va-
riety of tissues throughout the vascular and lymphatic systems [26] and may 
also participate in heparin clearance within the liver [15,27]. 
In this report, we demonstrate the use of synthetic homogenous hep-
arin (HS) of a defined size (12mer/dodecamer) and compare two polymers 
which do (12mer) or do not (n12mer) contain a single 3-O sulfation on GlcNS 
(Fig. 1A) [13,28,29]. These polymers and other similarly sized heparins have 
been previously used to determine robust binding and internalization by 
both Stabilin-1 and Stabilin-2 receptors [29]. These receptors are similar to 
each other [30], though they differ in expression levels, distribution, and af-
finity for heparin; Stabilin-2 having the highest affinity and higher expres-
sion in the liver sinusoids [15,31]. The objectives of this study are to deter-
mine the contribution of the 3-O sulfation of the dodecamer (LMWH) in the 
clearance of homogenous heparins in a WT mouse model and the contri-
bution of these receptors to heparin cellular endocytosis in knock-out mice. 
2. Methods and materials 
2.1. Animals 
Animals were used in accordance with the Institutional Animal Care and Use 
Committee at the University of Nebraska under breeding protocol #1235 and 
use protocol #1435. Stabilin-2 knock-out mice were a kind gift from Prof. At-
sushi Miyajima at the University of Tokyo and have been previously charac-
terized [32]. The Stabilin-2 knock-out strain was developed in the C57BL/6 
background. Stabilin-1 knock-out mice was developed in the C57BL/6 back-
ground by Jackson Laboratories using CRISPR/CAS9 technologies to delete 
the 2nd exon of the gene to produce a non-productive mRNA (supplemen-
tal Fig. 1). Both KO strains are homozygous and phenotypically the same 
as reported previously by Schledzewski et al. [27] and verified by the use of 
Phire Direct PCR Master Mix (Thermofisher). Male C57BL/6 mice (9–13 weeks 
old) were lightly anesthetized with 30% isoflurane mixed with polyethylene 
glycol 200 and injected subcutaneously with 100 μL of 35S-labeled heparan 
sulfate compound mixed in phosphate buffered saline for a final administra-
tion of 0.43 mg/kg body weight. Immediately following injection, the mice 
were placed in a metabolic cage containing food and water ad libitum. At 
the designated time point, mice were anesthetized with 30% isoflurane and 
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Fig. 1. Structure and purity of the dodecamers. A) Schematic representation of the 
3-O sulfated (red highlighted modification) and non-3-O sulfated dodecamers used 
in this study. B) DEAE-HPLC chromatograms of 12mers. Both 12mers were eluted in 
a single peak, indicating that the compounds were pure.  
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blood, urine, liver and kidneys were collected. Blood was centrifuged in a Z 
serum Sep Clot Activator vacutainer tube (Greiner Bio-one) and 0.1 mL se-
rum was mixed with 4 mL scintillation fluid. Total blood volume was calcu-
lated as 7% of body weight by volume. Total urine was collected from both 
the cage and mouse and 10% of the volume was mixed with 4 mL scintilla-
tion fluid and counted. The remaining 90% of urine and remaining serum 
was retained for the degradation assay. Small pieces of liver, approximately 
0.1 g, were cut, weighed, and homogenized in 1% NP-40. Kidneys were cut 
in half, weighed, and homogenized in 1% NP-40. The homogenized tissues 
were centrifuged at 6100×g for 2 min to separate out the solids and the liq-
uid fraction was mixed with 4 mL scintillation fluid and counted. 
2.2. Synthesis and purification of the 35S-labeled and biotinylated 
dodecamers 
35S-labeled synthetic n12mer was prepared from the synthetic precursor 
12mer without 6-O-sulfate groups, GlcNS-GlcA-(GlcNSIdoA2S)4-GlcNS-GlcA-
pNP synthesized by following the published method [14,33]. The 35S-sul-
fate was introduced to the 12-mers by heparan sulfate 6-O-sulfotransfer-
ases. Briefly, the reaction consisted of 2-(N-morpholino)ethanesulfonic acid 
(MES) 50 mM, pH 7.0, 6-O-sulfotransferase 1 (6-OST-1) 0.1 mg/mL, 6-O-sul-
fotransferase 3 (6-OST-3) 0.1 mg/mL and 2 nmol 35S-labeled 3′-phospho-
adenosine 5′-phosphosulfate ([35S]PAPS) (2×107 cpm) and precursor 12mer 
(2 mg) in a total volume of 0.5 mL. After incubation at 37 °C for 3 h, the 6-O-
[35S] sulfo group was incorporated into the 12-mer precursor, but the 6-O-
sulfation to 12-mer precursor was still incomplete. To this end, an additional 
round of 6-O-sulfation using unlabeled PAPS to complete the 6-O-sulfation 
step. Here, MES 50mM pH 7.0 buffer, 6-OST-1 0.5 mg, 6-OST-3 0.5 mg, and 
30 μmol unlabeled PAPS were add in a total volume of 0.5 mL, then incu-
bated at 37 °C overnight. 
HS 12mers with pNP tag (Fig. 1A) (4 mg) and 0.5 mg Pd/C were dis-
solved in 20mM NaOAc, pH 5.0 in a total volume of 4 mL. Reaction mixture 
was vacuumed and refilled with H2 three times. The reaction was then incu-
bated at room temperature for 4 h. It was then filtered to remove charcoal. 
The flow through was adjusted to pH 8.5 using 500mM Na2HPO4. Succinimi-
dyl 6-azidohexanoate (8M equivalent of 12mer) was added and incubated at 
37 °C overnight. Reaction was purified by DEAE-HPLC column to generate 
azido tagged 12mers. PBS (pH 7.4) buffer was bubbled using N2 for 5 min 
for preparing the sample solution of 0.1M CuSO4, 0.1M Tris(3-hydroxypro-
pyltriazolylmethyl) amine (THPTA) (Sigma), 0.15M sodium ascorbate, 0.01M 
azido tagged 12mer and 0.02M biotin-PEG4-alkyne (Sigma). Mixture of 200 
μL THPTA and 40 μL CuSO4 was vortexed, then 80 μL sodium ascorbate, 100 
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μL 12mer and 100 μL biotin-PEG4-alkyne (from Sigma) was added and bub-
bled using N2 for 2 min, then incubated at 37 °C overnight. Reaction was pu-
rified by DEAE-HPLC column to generate biotinylated 12mers. HPLC and MS 
were used to monitor above reactions. 
The synthesis of 35S-labeled 12mer was accomplished by converting the 
non-3-O sulfated 12mer (n12mer) to 12-mer. The reaction consisted of MES 
50mM pH 7.0, 10mM MnCl2, 5mM MgCl2, 3-OST-1 0.1 mg/mL and 1 μmol 
PAPS and n12mer (1 mg) in a total volume of 1 mL at 37 °C overnight. Both 
n12mer and 12mer were purified by a diethylaminoethyl (DEAE)-HPLC col-
umn [29]. Briefly, the DEAE-NPR column (Tosohaas) was eluted with a linear 
gradient of NaCl in 20mM sodium acetate buffer (pH 5.0) from 0 to 1M in 
60 min at a flow rate of 0.4 mL/ min. 
2.3. Isolation and purification of primary liver sinusoidal endothelial cells 
(LSECs) 
The purification of LSECs has been published previously [34,35]. Briefly, an 
anesthetized mouse had its abdomen exposed and portal vein catheterized 
with a 24G×0.75 in. catheter and the liver was flushed with phosphate-buf-
fer saline at a flow rate of 4 mL/min. The liver was then digested with Type 1 
collagenase (Worthington, Lakewood, NJ) at a concentration of 0.5 mg/mL 
in 45 mL for 12 min or until the volume was completely used up. Differen-
tial centrifugation separated hepatocytes from non-parenchymal cells and 
LSECs were enriched on a 25/50% Percoll gradient, separated from Kupffer 
cells by selective adhesion on polystyrene plates, washed and plated in col-
lagen-coated 24-well tissue culture polystyrene plates and allowed a 2 h re-
covery prior to the experiment. 
2.4. Cell lines 
Established human Stabilin-2 and Stabilin-1 cell lines are described previ-
ously [36]. Briefly, the stab2 cDNA was cloned from human spleen tissue 
and the stab1 cDNA was a kind gift from Dr. J. Kzhyshkowska. Both stab 
cDNAs were inserted in pcDNA5/FRT/V5/His6-TOPO (Thermofisher) and 
named pcDNA5-hStab2 or pcDNA5-hStab1 [15]. The mouse Stabilin-2 cell 
line used in these experiments was generated in the same manner and has 
not been previously reported. We have compared it with the human Stabi-
lin-2 cell line in terms of both expression level and receptor activity using 
a well-established ligand (Supplemental Fig. 2). Stable cell lines were cre-
ated from 293 Flp-In cells by the transfection of 9.0 μg pOG44 and 1.0 μg 
pcDNA5-hStab2 or pcDNA5-hStab1 or pcDNA5-mStab2 (mouse) and 20 μL 
Lipofectamine 2000 in a 100mm dish followed by the addition of selection 
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media (DMEM+8% FBS+50 μg/mL hygromycin B) 24 h later and stable col-
onies were selected about 2 weeks post-transfection. Clones were assessed 
for recombinant protein expression, normal morphology and were β-gal 
negative (for correct insertion within the FRT site in the genome). 
2.5. Degradation assay 
The collected degraded samples were run through DEAE column following 
the procedure described previously [37]. The collected samples were mixed 
with 1 mL of 0.01% Triton X-100 buffer at pH 5.0 containing 150mM NaCl, 
50mM NaOAc, 3M urea, 1mM ethylenediaminetetraacetic acid (EDTA) be-
fore they were transferred to a small DEAE column (200 μL in size). The col-
umn was then washed three times with the same buffer, 1 mL each wash. 
The column was further washed three times with 0.25M NaCl in 0.001% Tri-
ton X-100 buffer, 1 mL each wash. The column was eluted with 1 mL of 2M 
NaCl in 0.001% Triton X-100 buffer. The wash flow-through and the eluted 
samples were collected and the cpm of 35S was measured by a scintillation 
counter. The eluted samples were analyzed by DEAE-HPLC to determine the 
elution time of the 35S-labeled peak and compared with the elution time of 
intact 12mer.  
2.6. Endocytosis assay 
Endocytosis assays for the 35S-dodecamers and 125I-streptavidinbiotinylated 
dodecamers have been described previously [15,38]. Endocytosis of bioti-
nylated dodecamers was performed with 47 nM 125Istreptavidin pre-mixed 
with 190 nM biotinylated dodecamer. The negative control was incubated 
with 125I-strepatvidin alone and subtracted from the experimental values to 
calculate specific binding/endocytosis. Endocytosis of 35S-dodecamers was 
assessed to “test” out the reagent on Stabilin-2 expressing cell lines and 
empty vector control cell lines before it was used on animals. In each case, 
cells were evaluated in 24-well plates, lysed in 0.3 mL 0.3M NaOH and as-
sessed with a gamma counter for 125I or in a scintillation counter for 35S and 
normalized for protein content using the Bradford assay. 
2.7. Statistics 
The number of animals used in these experiments was at least 5 per time 
point and the data was calculated as mean ± standard deviation. Signif-
icance was assessed by t-test at a 95% confidence level using SigmaPlot 
11.2 software. 
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3. Results 
The objective of this study was to determine the contribution of the 3-O 
sulfate modification of this synthetic LMWH in hepatotropic metabolism. To 
do this, we used homogenous chemoenzymatically designed heparan sul-
fate oligomers that were known to interact with the Stabilin receptors [15]. 
The size of each oligo is 12 sugars long (dodecamer) consisting of 14 sul-
fate groups arranged as N- and 6-O sulfated GlcNS and 2-O sulfated idu-
ronic acid. One set of oligos was 3-O sulfated on the 1st GlcNS (3rd sugar) 
from the non-reducing end for a total of 15 sulfated groups and is referred 
to as the “12mer” in contrast to the “n12mer” which is not 3-O sulfated (Fig. 
1A). After the synthesis was complete, each oligo was assessed for purity 
by HPLC trace (Fig. 1B). The full characterization of their structure by mass 
spectrometry and NMR in addition with their anticoagulant profile against 
Factor Xa was previously reported by Xu et al. [29]. Generally, 6-O- [35S]sul-
fated 12-mers were used for metabolic studies within mice and biotinylated 
12-mers were used for cell based assays. The biotin was conjugated to the 
reducing end of the terminal GlcA via the p-nitrophenol (pNP) linker (in Fig. 
1 biotinylated HS) [39]. 
To verify that the oligos had similar affinities for the human Stabilin re-
ceptors, we performed cell-based endocytosis assays with each new prep-
aration of HS oligo. Similar to previously published experiments [29], the 
oligos that we used have a high affinity for 190-HARE cells which are cells 
expressing the small isoform of human Stabilin-2 and low affinity for the 
parent/empty vector cell line (Fig. 2A). We next compared the affinity of the 
biotinylated 12mer (Fig. 2B) and n12mer (Fig. 2C) labeled with 125I-strepta-
vidin with human and mouse Stabilin- 2 and human Stabilin-1 in a com-
parative study to determine that both human and mouse receptors have 
the same binding/endocytosis activity for the ligand. This data is also use-
ful to determine the validity of our animal models with relevance for hepa-
rin metabolism in humans. Both Stabilin-1 and Stabilin-2 lines internalized 
the oligos with approximately the same rate for 2 h, though accumulation 
was greater in the Stabilin-2 line over a 6 h time course than in the Stabi-
lin-1 line (data not shown). 
To assess the contribution of the 3-O sulfate modification in heparin me-
tabolism, radiolabeled dodecamers with and without the 3-O sulfation were 
subcutaneously injected in mice at a concentration of approximately 0.43 
mg/kg, though the molar ratio of polymers that would act against the co-
agulation factors is higher in homogenously prepared samples than in the 
natural heterogeneous LMWH sample. This dose is similar to a standard in-
jection of 40 mg of LMWH in an 80 kg human patient. Immediately after 
the injection, individual mice were placed in a metabolic cage for the collec-
tion of urine. At each time point, mice were anesthetized and tissues/fluids 
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Fig. 2. Internalization of dodecamers in Stabilin expressing cell lines. A) dodecam-
ers labeled directly with 35S were allowed to be internalized by 190- HARE (small 
isoform of Stabilin-2) expressing cells and empty vector (EV) cells for 3 h. Cells were 
washed, lysed in 0.3 N NaOH and 90% of the lysate was mixed with scintillation 
fluid and evaluated by a scintillation counter. The remaining 10% of the lysate was 
evaluated for protein content by the Bradford assay. B) Biotinylated 12mer and C) 
biotinylated n12mer were conjugated with 125I-streptavidin and incubated with EV, 
human Stabilin-1, human Stabilin-2, and mouse Stabilin-2 expressing cell lines for 
2 h. Cells were washed 3 times with HBSS, lysed in 0.3 mL 0.3 N NaOH, and evalu-
ated by a gamma counter. Total protein content was evaluated by the Bradford as-
say. All data presented is the mean ± standard deviation, n = 4.  
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were collected (urine, blood, liver, and kidneys) and assessed for radioac-
tivity and normalized by body weight. The contribution of a single 3-O sul-
fate made a significant difference in metabolism of these HS dodecamers. 
In blood, the amount of 12mer spiked initially and then decreased over time 
with a half-life of about 90 min. The n12mer in blood did not show a signif-
icant spike and was cleared from blood roughly as soon as it was perfused 
in the circulation (Fig. 3A). To determine what had happened to both do-
decamers as they were cleared in blood, we obtained urine from the collec-
tion cups in the metabolic cages and combined it with any leftover urine in 
the bladder at the time of sacrifice. The n12mer rapidly accumulated in urine 
in contrast to the slower rate observed with the 12mer which accumulated 
slower and then leveled off at the 2 h point (Fig. 3B). The amount of 12mer 
in kidney stayed in the range of 0.08–0.11 pmol/mg kidney throughout the 
7 h time course of the experiment, in contrast to the n12mer which initially 
Fig. 3. Rates of accumulation of HS dodecasaccharides in tissues. Mice were sub-
cutaneously injected with 35S-12mer or 35S-n12mer and placed in a metabolic cage 
until the indicated time point. At the indicated time points, mice were anesthetized 
and A) serum, B) urine, C) kidney, and D) liver tissues were collected, weighted, and 
assessed for radioactivity. n = 5.  
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started out at a high of 0.13 pmol/mg and steadily decreased down to 0.02 
pmol/mg (Fig. 3C). The accumulation in liver was quite different, in that the 
12mer steadily increased and peaked at 0.31 pmol/mg at 3 h and then de-
creased steadily to 0.16 pmol/mg by 7 h. This is in contrast to the n12mer 
which peaked at only 0.08 pmol/mg within the first 30 min and slowly de-
creased to near zero over 7 h. 
Next, we examined the data as a ratio of both urine to liver and serum 
to liver to observe how dynamic the accumulation or clearance of each do-
decamer was in relation to the liver. For urine, the amount of n12mer in urine 
steadily increased over time in contrast to the 12mer which did not increase 
at all—suggesting that the n12mer is not retained within the liver (Fig. 4A). 
In serum, the 12mer initially starts very high and decreases at a parabolic 
rate to near zero at 7 h. This is in contrast to the n12mer which levels off 
early and maintains a low concentration, suggesting that the n12mer clear-
ance is independent of liver activity (Fig. 4B). 
Whether the dodecamers are cleared by kidney or liver, they are de-
graded over the 7 h time course. To determine the amount of degradation 
Fig. 4. Accumulation ratios for 3-O sulfated and non-3-O sulfated in tissues. The 
accumulated radioactivity in either A) urine or B) serum was divided by the liver ra-
dioactivity counts at each time point. n = 5.  
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in either urine or serum, we ran our samples over a DEAE anion exchange 
column to separate intact versus degraded polymers. Degraded material 
is easily washed off in 0.25M NaCl, whereas, intact polymers have a higher 
affinity for the column and only wash off as the column is regenerated in 
high salt (2M NaCl). The eluted 12mers from an anion exchange column 
with 2M NaCl were analyzed by DEAEHPLC. The DEAE-purified 35S-labeled 
component from urine or serum samples showed the same elution profile 
on the DEAE-HPLC as that of intact 12mers. The results suggest that the 35S-
counts that bound to the anion exchange column represent the undigested 
12-mers. Based on the calculation of the ratio of 35S-counts in the wash-off 
fractions and the eluted fractions, we estimated the amount of degradation 
of 12-mers. The n12mer had a much higher rate of degradation compared 
to the 12mer in serum, though both reached the same percentage of deg-
radation by 7 h (Fig. 5A). The percentage of degraded material in urine was 
Fig. 5. Degradation of HS dodecasaccharides in urine and serum. At each time point, 
A) serum and B) urine were collected and fractionated over a DEAE column and 
counts were assessed by a radiological counter. For serum, each time point is signif-
icantly different (p < 0.01) except the last (7 h) time point. For the urine, there was 
no significant difference between the HS oligos at all time points (p ≥ 0.05), n = 5. 
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the same for both dodecamers suggesting that clearance mechanisms for 
clearing dodecasaccharides in kidney is different from liver (Fig. 5B). 
Finally, as liver mediated degradation is performed by the liver sinusoi-
dal endothelial cells (LSECs) and not by other cells within the liver [8,40], we 
purified mouse LSECs from WT, Stabilin-1 KO and Stabilin-2 KO mice and 
assessed their ability to internalize different ligands. The difference in HA 
internalization between the WT and Stab1 KO in contrast to the Stab2KO 
mice is expected (p < 0.001) as HA uptake is very specific for the Stabilin-2 
receptor (Fig. 6A). In contrast, UFH uptake in in WT and Stab1 KO cells was 
nearly identical and was trending less, though not significantly (p=0.08), in 
the Stab2 KO cells (Fig. 6B). The statistical difference for n12mer uptake be-
tween WT and Stab1 KO cells was not significant though there was a statis-
tical difference between WT and Stab2 KO cells (Fig. 6C). The difference in 
Fig. 6. Endocytosis of ligands by primary liver sinusoidal endothelial cells (LSECs). 
LSECs from WT, Stab1 KO and Stab2 KO mice were purified, plated on collagen, and 
allowed to recover for 2 h. Cells were then incubated with either A) 125I-Hyaluro-
nan, B) 125I-SA-b-UFH, C) 125I-SA- 12mer and D) 125I-SA-n12mer for 2.5 h, washed 3 
times in HBSS, lysed in 0.3 N NaOH and assessed for radioactivity and protein lev-
els by the Bradford assay. Data are the mean ± standard deviation; n = 3–6. N.S. = 
not significant; * p < 0.001 ; # p = 0.011 ; + p = 0.08.  
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uptake was significantly higher in both Stab1 and Stab2 KO cells when ex-
amined for 12mer endocytosis (Fig. 6D) suggesting that the 3-O sulfate on 
the HS polymer plays a significant role in the clearance of this molecule via 
the Stabilin receptors. 
4. Discussion 
We have demonstrated that the 3-O modification of a heparin polymer 
changes the metabolic route of the molecule. With this modification, the 
polymer may bind with coagulation cofactors in the blood and other endo-
thelial cell receptors and molecules to prevent rapid clearance by the kid-
ney. We have also observed that the increased blood residence allows for 
increased exposure for binding with the Stabilin receptors which allow the 
heparin to be internalized within the liver. In cell culture, 3-O sulfated 12mers 
are rapidly taken up by Stabilin expressing cells in contrast to non-3-O sul-
fated 12mers (this study and [29]). The impact of 3-O sulfation on metabo-
lism is that there is lower accumulation in the kidneys. Although somewhat 
controversial, one of the common adverse side-effects of LMWH (enoxapa-
rin and not tinzaparin) is bioaccumulation and bleeding that occurs in pa-
tients which may be problematic for individuals with renal disease [41,42]. 
These dodecamers would be classified as LMWH due to their molecu-
lar mass and the 3-O sulfated species has a much higher molar ratio of this 
modification than natural LMWH, potentially allowing for a lower dose to 
achieve similar bioactivities. Thus, the 12mer is characterized as a heparin 
species that has the qualities of both LMWH and UFH. The 12mer:Factor Xa 
(FXa) interaction has about half the activity as the UFH:FXa interaction, but 
much higher than natural LMWH or Fondaparinux suggesting that the 12mer 
may be a good candidate to replace natural LMWH as a prophylactic [29]. 
A more recent study has shown that a similar dodecamer, the super-12mer 
(s12mer), containing 2 3-O sulfation modifications is similar to Enoxaparin 
with regards to FXa activity, but is reversible with protamine treatment simi-
lar to UFH, thus making it suitable as a heparin analog with enhanced safety 
[43]. We would argue that a single 3-O sulfation on a 12mer is not quite as 
potent for FXa activity or neutralization by protamine treatment, but shows 
us that the contribution of this modification directs the catabolism of the 
oligo away from immediate filtration by the kidney. We have compared the 
12mer and super 12mer (s12mer), a dodecamer with two 3-O sulfated mod-
ifications, with regards to binding and endocytosis in the 315-HARE (Stabi-
lin-2) cell lines using the 35S tracer and found the s12mer is typically slightly 
higher in both categories though the difference may or may not be signifi-
cant, suggesting that these two polymers are nearly identical in recognition 
of the Stabilin-2 receptor (Supplemental Fig. 3) [29]. Of course, this is only 
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relevant with the Stabilin:oligo interaction and may not directly impact FXa 
activity or other coagulation factors. 
The binding site for heparin on the Stabilin receptors is not an obvious 
string or patch of basic residues and the overall structure for the receptor is 
unknown at this time. Binding specificity of heparin is not solely due to their 
high negative charge, but also the specificity of the sugar pattern. For exam-
ple, we already know from previous work heparin may be competed much 
better by 4,6-disulfated chondroitin sulfate rather than by 2,6-disulfated 
chondroitin sulfate even though the overall charge of both CS polymers 
is the same [38]. Here, we propose that the interaction of the 3-O sulfated 
GlcNS with the Stabilins has more to do with specificity of this modifica-
tion within a binding pocket than charge alone. The full-length Stabilin-2 
protein has 204 cysteine residues tied up in disulfide linkages and a subset 
of these are responsible for the folding of 20 epidermal growth factor do-
mains and one X-Link domain [36]. Hyaluronan binds within the X-link do-
main and is not competed by heparin [38] nor is the X-link domain even 
required for heparin binding [44], unlike the closest homologous XLink do-
main in TSG-6 [45]. The dodecamers fulfill the requirement for full binding 
to the receptor as 10 sugars is the minimum for binding detection [15]. Cer-
tainly, the exploration of individual contributions of both Stabilin-1 and Sta-
bilin-2 in the clearance of heparin and other high negatively charged mol-
ecules is on-going. 
We know that the Stabilin receptors are major clearance receptors for 
heparin, but are likely assisted by other receptors on the cell surface. Due to 
their charge, heparins are “sticky” molecules and may bind to a multitude of 
proteins on the cell surface, but few of those proteins are professional recy-
cling receptors. The Stabilin-2 KO LSECs internalized heterogeneous heparin 
(UFH) at nearly the same rate as the WT. This may be due to the presence 
of Stabilin-1 in these cells and other receptors that may respond to the lack 
of the presence of Stabilin-2. The Stab2KO LSECs had lower internalization 
rates of both n12mer and 12mer suggesting that Stabilin-2 has a higher af-
finity for the HS molecule than Stabilin-1. A single knockout of either Stabilin 
receptor did not significantly impact UFH uptake. There may be two expla-
nations for this. First, the remaining Stabilin receptor may serve to compen-
sate for the loss of the companion Stabilin receptor in these cells. Second, 
there is a high probability that there are other receptors or molecules on 
the surface of the LSEC that may bind with heparins [46]. These may or may 
not be professional recycling receptors, but the cumulative effect is signifi-
cant for heparin metabolism. When we compare our cell lines which are in 
the HEK 293 background with LSECs from either mice or rats, the cell lines 
are much cleaner and demonstrate lower background binding activity (see 
Fig. 2) than the primary cells. This suggests that there are other molecular 
factors in the primary cells that work in parallel with the Stabilin receptors. 
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In our experiments, we demonstrated that endocytosis of both the n12mer 
and 12mer are significantly impacted by Stabilin-2 suggesting that this re-
ceptor is a major contributor for heparin clearance. 
5. Conclusions 
The 3-O sulfation modification of synthetic homogenous heparin increases 
half-life in the blood and directs the catabolism to the liver rather than the 
kidney. Both Stabilin-1 and Stabilin-2 receptors recognize the 12mer with 
higher affinity than the n12mer and the affinity of these ligands for Stabi-
lin-2 exceeds Stabilin-1.   
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Supplemental Fig. 1
Supplemental Fig. 1:  Genotype of the Stabilin-1 
KO mouse line.  This KO mouse line was 
developed by Jackson Laboratories in which the 
2nd exon of the gene was deleted (dark gray 
region) by guide RNAs targeting flanking regions 
(green regions).  The homozygous deletion in the 
mice was verified by PCR (cyan regions).  The 
image of the gel shows WT parent (+/+), 
homozygous KO (-/-), and heterozygous KO (+/-) 
with the black arrow indicating the intact exon 2 
and red arrow indicating the same amplicon with 
the exon 2 deletion.  Only homozygous, not 
heterozygous Stabilin-1 KO mice were used in this 
study.
Hrs























































































Supplemental Fig. 2: Characterization of the mouse Stabilin-2 expressing cell 
line.  A) 293 Flp-In cells were stably transfected with mouse Stabilin-2 cDNA in 
pcDNA5/FRT/V5-6xHis and a clone with similar receptor expression levels to 
the human cell line was chosen using the criteria outline in the methods and 
materials section.  B) Densitometry of the Stabilin-2 receptor in relation to 
expression of the housekeeper protein, Vinculin.  C) The recombinant mouse 
line was compared with the human line for 125I-HA internalization and found 
to be nearly identical.
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Supplemental Fig. 3:  Endocytosis rates of 12mer and s12mer.  Human Stabilin-2 (315-
HARE) cells were plated in 24-well plates, allowed to grow up to 80% confluency over 2 
days and then incubated with a single 3-O-sulfated or double 3-O sulfated dodecamer
over a 2.5 hr time course.  At each indicated time point, cells were washed 3x with HBSS 
and lysed in 0.3 mL 0.3 N NaOH.  Radioactivity was evaluated with a scintiallation counter 
and protein was measured by the Bradford assay. n=3, mean±std. deviation.
